Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ventrus Biosciences Completes Enrollment of Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease
Results Are Anticipated in Late June to Early July - 2012
View HTML
Toggle Summary Ventrus Announces Two Studies Addressing Hemorrhoid Disease to be Presented at Digestive Disease Week Conference
NEW YORK , March 8, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced today that two abstracts submitted to the Digestive Disease Week conference (DDW), to be held in San Diego May 19-22 , were accepted for presentation. Both abstracts present data from the omnibus patient
View HTML
Toggle Summary Ventrus to Present at the 24th Annual ROTH OC Growth Stock Conference
NEW YORK , March 5, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison , Chairman and Chief Executive Officer, will be presenting at the 24 th Annual
View HTML
Toggle Summary Ventrus to Present at Cowen and Company 32nd Annual Health Care Conference
NEW YORK , Feb. 28, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison , Chairman and Chief Executive Officer, will be presenting at the Cowen and
View HTML
Toggle Summary Ventrus Announces Publication of Prior Phase 2b Study on the Safety and Efficacy of Iferanserin in the Treatment of Hemorrhoid Disease
NEW YORK , Jan. 13, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), today announced the online publication of the prior Phase 2b study utilizing iferanserin (VEN 309), its novel investigational drug for the treatment of symptomatic hemorrhoids, in the peer reviewed journal
View HTML
Toggle Summary Ventrus BioSciences Completes Enrollment of Pivotal Phase 3 Trial of Diltiazem (VEN 307) in Patients With Anal Fissures
Expects to Deliver Top Line Results From Pivotal Trial in May-2012
View HTML
Toggle Summary Ventrus Announces Acquisition of Title to Hemorrhoids Product
NEW YORK , Nov. 18, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that on November 14, 2011 it completed its acquisition of all rights and title to VEN 309 (iferanserin) from the licensor, Sam Amer & Co. The total price paid for the asset was US$12.5 million
View HTML
Toggle Summary Ventrus Reports Third Quarter 2011 Financial Results
NEW YORK , Nov. 14, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) today reported financial results for the third quarter ended September 30, 2011 . In July, Ventrus received net cash proceeds of $47.5 million after closing a secondary public offering.
View HTML
Toggle Summary Ventrus Validates Large Patient Potential for VEN 309 With Survey Data From 10,000 Consumers
Expects to Deliver Top Line Results From Two Pivotal Trials in Mid-2012 and to Complete the Acquisition of the Global Rights and Title for VEN 309 From the Licensor
View HTML
Toggle Summary Ventrus BioSciences to Announce 3Q 2011 Financial Results, Clinical Update and Omnibus Market Research Results: Conference Call and Webcast
NEW YORK , Nov. 9, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it will report on its clinical trial progress, the initial topline results of a market research study commissioned by it and conducted by Princeton Biometrics on the U.S.
View HTML